News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,839 Results
Type
Article (154)
Company Profile (1)
Press Release (1684)
Section
Business (699)
Career Advice (1)
Deals (107)
Drug Development (322)
Employer Resources (4)
FDA (63)
Job Trends (40)
News (1194)
Policy (109)
Tag
Academia (2)
Adcomms (1)
Alliances (161)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (8)
Approvals (65)
Artificial intelligence (2)
Bankruptcy (1)
Best Places to Work (23)
Biotechnology (1)
Brain cancer (1)
Cancer (13)
Career advice (1)
Clinical research (305)
Collaboration (4)
C-suite (2)
Data (15)
Diagnostics (5)
Diversity, equity & inclusion (1)
Earnings (265)
Employer branding (1)
Employer resources (3)
Events (190)
Executive appointments (8)
FDA (70)
Funding (2)
GLP-1 (3)
Government (8)
Guidances (3)
Healthcare (25)
Indications (1)
Infectious disease (1)
IPO (47)
Job creations (18)
Job search strategy (1)
Kidney cancer (1)
Layoffs (6)
Legal (6)
Lymphoma (1)
Management (1)
MASH (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (63)
Metabolic disorders (2)
Neuroscience (1)
NextGen: Class of 2025 (9)
Non-profit (7)
Obesity (1)
Opinion (1)
Pancreatic cancer (3)
People (273)
Phase I (54)
Phase II (94)
Phase III (178)
Pipeline (13)
Postmarket research (3)
Preclinical (10)
Prostate cancer (2)
Psychedelics (1)
Rare diseases (3)
Real estate (14)
Recruiting (1)
Regulatory (103)
Research institute (2)
RSV (1)
Series A (2)
Startups (15)
The Weekly (1)
Date
Last 30 days (8)
Last 365 days (104)
2025 (52)
2024 (115)
2023 (146)
2022 (198)
2021 (164)
2020 (146)
2019 (126)
2018 (103)
2017 (107)
2016 (79)
2015 (79)
2014 (74)
2013 (50)
2012 (62)
2011 (65)
2010 (69)
Location
Africa (2)
Asia (55)
Australia (3)
California (19)
Canada (6)
China (2)
Europe (905)
Florida (1)
Illinois (3)
Maryland (2)
Massachusetts (24)
New Jersey (1)
New York (2)
Northern California (14)
South America (3)
Texas (1)
United States (55)
Wisconsin (1)
1,839 Results for "ipsen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
May 21, 2025
·
5 min read
Press Releases
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
May 6, 2025
·
6 min read
Press Releases
Ipsen S.A. - Annual General Meeting held on 21 May 2025
May 22, 2025
·
6 min read
Press Releases
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
May 1, 2025
·
6 min read
Press Releases
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
April 16, 2025
·
7 min read
Press Releases
Ipsen announces issuance of €500 million inaugural Rated Public Bond
March 19, 2025
·
8 min read
Press Releases
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
March 12, 2025
·
6 min read
Press Releases
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
April 29, 2025
·
8 min read
Press Releases
Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen
March 4, 2025
·
2 min read
Drug Development
Gilead, Ipsen Tout Phase III Primary Biliary Cholangitis Data as PDUFA Dates Loom
Gilead Sciences’ primary biliary cholangitis candidate seladelpar and Ipsen’s PBC asset elafibranor both showed encouraging Phase III results Wednesday, as they face looming FDA decision dates.
June 5, 2024
·
2 min read
·
Tyler Patchen
1 of 184
Next
